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ABSTRACT: Noonan syndrome (NS) is among the most
common nonchromosomal disorders affecting develop-
ment and growth. NS is caused by aberrant RAS-MAPK
signaling and is genetically heterogeneous, which ex-
plains, in part, the marked clinical variability documen-
ted for this Mendelian trait. Recently, we and others
identified SOS1 as a major gene underlying NS. Here, we
explored further the spectrum of SOS1 mutations and
their associated phenotypic features. Mutation scanning
of the entire SOS1 coding sequence allowed the
identification of 33 different variants deemed to be of
pathological significance, including 16 novel missense
changes and in-frame indels. Various mutation clusters
destabilizing or altering orientation of regions of the
protein predicted to contribute structurally to the
maintenance of autoinhibition were identified. Two
previously unappreciated clusters predicted to enhance
SOS1’s recruitment to the plasma membrane, thus
promoting a spatial reorientation of domains contributing
to inhibition, were also recognized. Genotype–phenotype
analysis confirmed our previous observations, establish-
ing a high frequency of ectodermal anomalies and a low
prevalence of cognitive impairment and reduced growth.
Finally, mutation analysis performed on cohorts of
individuals with nonsyndromic pulmonic stenosis, atrial
septal defects, and ventricular septal defects excluded a
major contribution of germline SOS1 lesions to the
isolated occurrence of these cardiac anomalies.
Hum Mutat 32:760–772, 2011. & 2011 Wiley-Liss, Inc.
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Introduction
Noonan syndrome (NS; MIM] 163950) is a relatively common
and clinically variable disorder characterized by postnatal reduced
growth, facial dysmorphism, and congenital heart defects (CHDs)
[Allanson, 1987; Noonan, 1994; Tartaglia et al., 2010; van der
Burgt, 2007]. The distinctive and most recurrent facial features
consist of a broad forehead, hypertelorism, down-slanting
palpebral fissures, ptosis, high arched palate, and low-set,
posteriorly rotated ears. Cardiac involvement is present in up to
80–90% of affected individuals, with pulmonic stenosis (PS),
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septal defects, and hypertrophic cardiomyopathy (HCM) occur-
ring most commonly [Burch et al., 1993; Marino et al., 1999].
Other associated features include multiple skeletal defects (chest
and spine deformities), webbed/short neck, variable cognitive
deficits, cryptorchidism, lymphatic dysplasia, bleeding diathesis,
and, rarely, predisposition to certain hematologic malignancies
during childhood.
NS is genetically heterogeneous, and, based upon the recent
discoveries of the underlying disease genes, is now regarded as a
disorder caused by enhanced signal flow through the RAS-MAPK
pathway [Tartaglia et al., 2010]. This signaling cascade is known to
mediate diverse biological functions, including cell proliferation,
survival, fate determination, and differentiation. It is activated in
response to cytokine, hormone, and growth factor stimulation,
and is a major mediator of early and late developmental processes
including morphology determination, organogenesis, synaptic
plasticity processes, and growth. In approximately 50% of affected
individuals, NS is caused by heterozygous missense mutations in
the PTPN11 gene [Tartaglia et al. 2001, 2002], which encodes a
cytoplasmic protein tyrosine phosphatase positively modulating
RAS function. Activating mutations in five additional genes
coding for transducers or modulatory proteins participating in
this signaling pathway (i.e., KRAS, NRAS, SOS1, RAF1, and BRAF)
account for an additional one-fourth of NS cases [Tartaglia et al.,
2010]. Mutations in these and other functionally related genes
(i.e., CBL, NF1, KRAS, HRAS, BRAF, SPRED1, SHOC2, MAP2K1,
and MAP2K2) have been reported to underlie clinically related
disorders [Aoki et al., 2008; Tartaglia et al., 2011; Tidyman and
Rauen, 2009]. Genotype–phenotype correlation surveys have
documented that the substantial phenotypic variation character-
izing NS can be ascribed, in part, to the gene mutated and even to
the specific molecular lesion involved.
We and others recently reported that missense mutations in
SOS1 (MIM] 182530) account for a significant proportion of NS
[Roberts et al., 2007; Tartaglia et al., 2007; Zenker et al., 2007a].
SOS1 encodes a guanine nucleotide exchange factor (GEF)
responsible for stimulating the conversion of RAS from the
inactive, GDP-bound to the active, GTP-bound form [Nimnual
and Bar-Sagi, 2002]. SOS1 is a large multidomain protein
characterized by an N-terminal regulatory portion including
tandem histone-like folds (HF), which are followed by a Dbl-
homology (DH) domain and a pleckstrin-homology (PH)
domain, and a C-terminal catalytic region including the RAS
exchanger motif (REM) and CDC25 domains, followed by a tail
providing docking sites for adaptor proteins required for receptor
anchoring (Fig. 1). The majority of NS-causing SOS1 mutations
were observed to affect residues predicted to be implicated in the
maintenance of SOS1 in its autoinhibited conformation, and the
first biochemical characterizations of mutants consistently docu-
mented enhanced protein function and increased signal flow
through RAS [Roberts et al., 2007; Tartaglia et al., 2007]. These
surveys also indicated that subjects heterozygous for a mutated
SOS1 allele tend to exhibit a distinctive phenotype that is
characterized by ectodermal abnormalities generally associated
with an absence of cognitive deficits [Tartaglia et al., 2007; Zenker
et al., 2007a]. We also observed that height was less frequently
below the third centile compared with the overall NS population
[Tartaglia et al., 2007]. Although available information supports
the view that SOS1 is not mutated in cardiofaciocutaneous
syndrome (CFCS; MIM] 115150) [Zenker et al., 2007a], a
condition clinically related to NS, a few individuals with
ectodermal manifestations and distinctive facial dysmorphism
that might be suggestive of CFCS have recently been reported has
having SOS1 mutations [Narumi et al., 2008; Nystrom et al.,
Figure 1. SOS1 domain structure and location of residues altered in Noonan syndrome. A: Schematic structure of SOS1 and variants
identified in the present study. SOS1 protein domains are indicated (DH, DBL homology domain; PH, pleckstrin homology domain; REM, RAS
exchanger motif; CDC25, CDC25 domain). Disease-causing mutations and probably pathogenetic/unclassified variants are shown above and
below the cartoon, respectively. Residues affected by class 1 mutations/variants are shown in red, while those affected by class 2 and class 3
changes are shown in yellow and green, respectively. Residues affected by substitutions with unpredictable effect on SOS1 function are shown
in black. Novel amino acid substitutions are underlined. B: Location of affected residues in SOS1 represented in its inactive conformation,
according to the crystal structure of the protein truncated at the C-terminus (residues 1–1049) (PDB ID: 3KSY) [Guerasko et al., 2010]. Ca ribbon
trace of the HF (sky blue), DH (sandy brown), PH (plum), REM (dark green), and CDC25 (blue) domains, and the helical linker connecting the PH
and REM domains (gray). Mutated residues are indicated with their side chains as thick lines and colored as reported above. Residue Asp309
(uncharacterized mutation p.Asp309Tyr) is shown in purple. Affected residues are listed in Supp. Table S2.
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2008]. In these subjects, cognitive deficits were generally absent or
minor, but at least one case with mental retardation was reported
[Narumi et al., 2008].
Here, we characterized further the molecular spectrum and
distribution of SOS1 mutations, as well as the phenotypic features
associated with those molecular defects. We also explored possible
involvement of germline SOS1 mutations in an opportunely
selected group of isolated CHDs that occur as an associated
feature in subjects with NS and heterozygous for a SOS1mutation.
Our results provide a more accurate description of the spectrum
of SOS1 gene defects, their consequence on SOS1 structure and
function, and their associated clinical features.
Materials and Methods
Patients
Four cohorts were included in the study. The first cohort (group
1) included 143 clinically well-characterized patients with NS
enrolled in research protocols. Nearly all subjects of this cohort
were of European ancestry, with the majority being Italian. Within
this group, subjects were assessed by clinical geneticists experienced
with NS and clinically related disorders (G.Z., M.C.D., L.M., B.D.,
G.B.F., M.C.S., A.S., I.K., G.N., M.F.F., A.P., F.S. and O.G.). Clinical
assessment included physical, anthropometric, neurologic, and
cardiac evaluations, as well as accurate examination for craniofacial
features, ophthalmologic, and otorhinolaryngologic defects, and
ectodermal and musculoskeletal anomalies. Clinical features for the
majority of these individuals satisfied diagnostic criteria reported
for NS [van der Burgt et al. 1994], but a few individuals with a
highly suggestive phenotype who lacked sufficient features to
receive a definitive diagnosis were also included. Based on scanning
of the coding exons by denaturing high-performance liquid
chromatography (DHPLC) analysis and/or direct sequencing, no
subject within this cohort harbored a mutation in PTPN11, KRAS,
or RAF1. For approximately half of the cases, mutations in BRAF,
MAP2K1, SHOC2, CBL, and NRAS had also been excluded. Besides
this large cohort, nine subjects with features fitting CFCS and no
mutation in KRAS, BRAF, MAP2K1, or MAP2K2 (group 2)
[Sarkozy et al., 2009a] were also included in the study. The third
cohort (group 3) (N5 358) comprised anonymous samples from
individuals with phenotypes suggestive of NS for whom commer-
cial DNA diagnostic testing was performed. Clinical data were not
available for these patients, and PTPN11 mutations had not
systematically been excluded in all the subjects included in this
group. Although the output obtained from genotyping this cohort
of subjects could not be used in genotype–phenotype correlation
studies or to estimate SOS1 mutation prevalence in the NS
population, the mutation data were utilized to provide a more
detailed picture about the molecular spectrum of disease-causing
mutations affecting the SOS1 gene. Finally, a cohort of 59 subjects
with nonsyndromic CHDs (PS, N5 21; atrial septal defects
(ASDs), N5 23; ventricular septal defects (VSDs), N5 15) was
included in the study (group 4). Clinical assessment of patients
with isolated CHDs included complete physical evaluation of
dysmorphism and malformations, anthropometric measurements,
renal ultrasonography, and radiological studies. Cardiac evaluation
included preoperative physical evaluation, chest X-ray film, 12-lead
electrocardiogram, and two-dimensional transthoracic echocardio-
graphy with color flow Doppler. Karyotype analysis was performed
in all patients of this cohort. Inclusion criteria were based on the
absence of any association with other clinical features, and
chromosomal anomalies, including the 22q11 deletion.
Informed consent for the genetic analyses was obtained from all
patients or their legal guardians.
Mutation Analysis
Genomic DNA was isolated from peripheral blood leukocytes
according to standard procedures. The entire SOS1 coding
sequence, as well as the exon/intron boundaries and flanking
intronic portions were scanned for mutations by direct sequencing
(group 3) or DHPLC analysis (groups 1, 2, and 4) with the use of
the 3100 and/or 3500HT Wave DNA Fragment Analysis System
(Transgenomic, Omaha, NE), at column temperatures recom-
mended by the Navigator version 1.5.4.23 software (Transge-
nomics), as previously described [Tartaglia et al., 2007]. Amplimers
having abnormal elution profiles were reamplified, purified
(Qiagen, Hilden, Germany) and sequenced using the ABI BigDye
Terminator Sequencing Kit v.1.1 (Applied Biosystems, Foster City,
CA) and an ABI 3700 Capillary Array Sequencer or ABI 3100
Genetic Analyzer (Applied Biosystems). Primer pair sequences as
well as PCR and DHPLC analysis settings are available upon
request. Length of deletions and dinucleotide mutations were
determined by cloning purified PCR products in a pCR 2.1 TOPO
vector (Invitrogen, Carlsbad, CA) and sequencing purified clones
(Plasmid Mini Kit, Qiagen). Nucleotide numbering of the
mutations and exonic disease-unrelated variants reflects cDNA
numbering with 1 corresponding to the A of the ATG translation
initiation codon in the reference sequence (NM_005633.3),
whereas position of the intronic variants were numbered according
to the reference genomic sequence (NG_007530.1).
The level of conservation of affected residues among ortholo-
gous SOS1 genes was evaluated by using the NCBI HomoloGene
tool (http://www.ncbi.nlm.nih.gov/homologene), while the SIFT
(Sorting Intolerant From Tolerant, http://blocks.fhcrc.org/sift/
SIFT.html) [Ng and Henikoff, 2001] and PolyPhen (Polymorph-
ism Phenotyping, http://genetics.bwh.harvard.edu/pph/) [Sunyaev
et al., 2000] software programs were used to predict the biological
relevance of the identified missense variants on protein function.
When available, parental DNAs were sequenced to establish
whether the identified changes in sporadic cases were de novo or to
confirm cosegregation between the variant and phenotype in
families transmitting the trait. Paternity was confirmed using the
AmpDESTER ProfilerPlus kit (Applied Biosystems). All missense
changes proven to be de novo by parental DNA genotyping were
deemed mutations causally linked to the disorder. To exclude the
possibility that variants cosegregating with NS were neutral
polymorphic changes occurring in the population, at least 300
population-matched DNAs obtained from unaffected subjects were
screened (DHPLC analysis and sequencing of variant elution
profiles). When parental DNAs were not available, we considered
a novel nonsynonymous variant as a causative mutation when it
affected a residue already reported to be mutated. Novel variants
involving residues localized in close proximity to residues mutated in
NS, predicted to affect protein structure/function by Polyphen, SIFT,
and structural evidence, but without sufficient genetic evidence (i.e.,
cases with unreported ethnicity or missing clinical evaluation
and/or genetic testing of other members of their families) were
considered as probably pathogenic. These missense changes were
found not to occur in controls, and resulted in a nonconservative
substitution at an invariant or highly conserved residue (Homo
sapiens [NP_005624.2], Pan troglodytes [XP_515425.2], Canis
familiaris [XP_540157.2], Bos taurus [XP_617859.4], Mus musculus
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[NP_033257.2], Rattus norvegicus [XP_233820.4], and Drosophila
melanogaster [NP_476597.2]). Finally, a third category grouping
functionally unclassified variants was considered for those novel
changes for which structural analysis did not allow to infer any
functional effect.
The position of mutated amino acid residues was modeled by
using the recently generated crystal structure of the SOS1 protein
truncated at the C-terminus (residues 1–1049) deposited in the
RCSB Protein Data Bank (http://www.rcsb.org/pdb/home/home.do)
(PDB ID: 3KSY) [Guerasko et al., 2010]. Figures were prepared
using the UCSF Chimera 1.5 software package (http://www.cgl.
ucsf.edu/chimera/) [Pettersen et al., 2004]. Electrostatic potential
calculations were performed with the APBS software [Baker
et al., 2001].
Statistical Analyses
Confidence intervals for proportions were calculated by means
of VassarStats software (http://faculty.vassar.edu/lowry/Vassar
Stats.html) using the Newcombe-Wilson method including
continuity correction [Newcombe, 1998; Wilson, 1927]. Genotype–
phenotype correlations were performed using 2 2 contingency
table analysis. The significance threshold was set at P5 0.05.
Results
SOS1 Mutation Scanning in NS, CFCS, and Isolated CHD
DHPLC analysis and bidirectional direct sequencing of the entire
SOS1 coding sequence on peripheral blood leukocyte genomic DNA
specimens of groups 1 and 3 identified 41 different heterozygous
missense nucleotide substitutions and three small in-frame indels in
108 unrelated subjects. Among them, five were private or common
variants unrelated with the trait. Three of them, c.1964C4T
(p.Pro655Leu), c.3032A4G (p.Asn1011Ser), and c.3959A4G
(p.His1320Arg, had previously been reported in unaffected
individuals [Roberts et al., 2007; Tartaglia et al., 2007]. Similarly,
the c.1705C4G (p.Leu569Val) was documented to occur as a
homozygous change in an unaffected parent, and the c.2122G4A
(p.Ala708Thr) was found to occur as a polymorphic change in
ethnic-matched unaffected individuals of Hispanic ancestry, and
were therefore regarded as benign polymorphisms. A full list of the
disease-unrelated changes, including silent nucleotide substitutions
and intronic variants, is reported in Supp. Table S1.
In these two cohorts, 25 SOS1 sequence variants were deemed to be
of pathological significance (Table 1). Among these, 17 had previously
been established as causative mutations (Supp. Table S2), whereas 8
were novel. Among the latter, five mutations were single nucleotide
substitutions, but three small in-frame indels affecting two mutational
hot spots within the PH domain (p.Lys427_Asp430delinsAsn and
p.Trp432_Glu433del) and the helical linker connecting the PH and
REM domains (PH-REM linker) (p.Leu554_Met558delinsLys) were
also identified. The c.1300_1301GG4AA (p.Gly434Lys) and
c.1310T4C (p.Ile437Thr) changes were demonstrated to occur
as de novo events by genotyping of parental DNAs. The
c.2681C4G transition (p.Pro894Arg) was found to cosegregate
with the disease, whereas the remaining two variants, c.1430A4G
(p.Gln477Arg) and c.1655G4T (p.Arg552Met), affected amino
acid residues that had previously been reported to be mutated in
NS (Supp. Table S2). Eight novel missense changes (p.Pro112Arg,
p.Ile252Thr, p.Met422Val, p.Glu424Lys, p.Gly482Arg, p.Leu490Arg,
p.Arg497Gln, and p.Thr549Lys) were considered as probably
pathogenic mutations. The majority of these variants were not
observed in more than 300 population-matched unaffected
individuals, and were nonconservative, the majority affecting
invariant residues among SOS1 orthologs and predicted to be
‘‘damaging’’ or have functional relevance according to the
PolyPhen or/and SIFT programs. Moreover, affected residues
were located in mutational hot spots or in close spatial proximity
to residues mutated in NS and were predicted to have structural/
functional consequences on protein structure (see below). For
these variants, however, the evidence provided by the theoretical
models and structural analysis was not unambiguously supported
by genetic evidence. Finally, six missense nucleotide substitutions
(p.Thr37Ala, p.Pro478Leu, p.Ile784Thr, p.Arg1131Lys, p.Leu1140Ile,
and p.Thr1257Ala) were classified as variants of unknown
significance. For those, parental DNAs were not submitted for
testing or no clinical information was available for the carrier
parent, and the predicted amino acid change was generally not
considered as having functional relevance according to the
PolyPhen or/and SIFT programs. Most of these changes affected
the C-terminal portion of the protein for which no structural
information is currently available, precluding any consideration
regarding possible consequences on protein function.
SOS1 mutations were identified in 26 of the 143 subjects
(18.2%) of group 1, which included patients with clinical features
satisfying the diagnostic criteria of NS or highly suggestive for the
disorder, and negative for mutations in PTPN11, RAF1, and
KRAS. Based on the accurate clinical assessment of this cohort and
the relative prevalence of mutations affecting those disease genes
in NS, this finding supports the view that mutations in the SOS1
gene account for approximately 10% of NS cases, which is in line
with our previous estimate [Tartaglia et al., 2007], but slightly
below those obtained from two other clinically well characterized
NS cohorts [Roberts et al., 2007; Zenker et al., 2007a].
DHPLC mutation scanning of coding exons, splice junctions,
and flanking intronic portions of SOS1 did not reveal any putative
pathogenic mutation in the nine subjects with a diagnosis of CFCS
and negative for mutations in BRAF, KRAS, MAP2K1, and
MAP2K2. Similarly, no mutation was identified among the 59
patients with nonsyndromic CHDs included in the study, excluding
a major involvement of germline SOS1 mutations in PS (N5 21;
95% confidence interval [CI]5 0.000–0.192), ASD (N5 23, 95%
CI5 0.000–0.178), and VSD (N5 15, 95% CI5 0.000–0.253).
SOS1 Mutation Diversity, Cluster Distribution, and
Molecular Modeling Analysis
The present data and available published records (updated to
July 2010) (Supp. Table S2) were utilized to analyze the diversity of
NS-causing mutations, their cluster distribution, and to explore
their effects on SOS1 structure and function. The 183 reported
missense mutations (including those with probably damaging
effects) were observed to affect 32 residues, which were not
randomly scattered along the protein but tended to cluster in
specific regions (Fig. 1). Approximately 40% of SOS1 defects
affected four residues located in the PH-REM linker (Ser548,
Thr549, Leu550, and Arg552), with substitutions of residue Arg552
accounting for one-third of all mutations. Another mutation
cluster, involving short stretches within the PH domain (i.e.,
Glu424, Trp432, Glu433, and Gly434, and Gln477, Pro478, and
Gly482) explained roughly 20% of mutations. A third functional
cluster (see below) resided at the interacting regions of the DH
(Thr266 and Met269) and REM (Lys728, Trp729, and Ile733)
domains (16% of total mutations). Among the most recurrent
mutations, the c.2536G4A transition, predicting the substitution
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of Glu846 by lysine within the CDC25 domain, accounted for 10%
of defects. Such a skewed distribution of affected residues implies
specific perturbing consequences on protein function.
SOS1’s GEF activity is controlled principally by two binding sites
for RAS: the catalytic site, which is located entirely within the CDC25
domain and promotes GDP release from RAS, and a distal site,
which is bracketed by the CDC25 domain and REM domains and
positively modulates GEF activity through promotion of a
conformational change at the active site that allows substrate GDP-
RAS to bind [Margarit et al., 2003]. Basally, the catalytic output of
SOS1 is constrained by the N-terminal regulatory HF domain and
DH-PH unit [Guerasko et al., 2010; Sondermann et al., 2004], and
structural data indicate that this autoinhibitory effect is exerted
through direct HF and DH domain-mediated blockade of the
allosteric site. An extensive interdomain binding network also
involving the PH-REM helical linker and the PH domain has been
recognized to stabilize this inhibitory conformation. Following the
translocation of SOS1 to the membrane, the inhibitory effect of the
HF and DH domains is relieved allowing RAS binding to the
allosteric site, which in turn, promotes a conformational rearrange-
ment of the CDC25 domain allowing RAS binding to the catalytic
site. Based on this allosteric mechanism of activation and recent
evidence indicating that the HF domain and the DH-PH unit are
conformationally coupled to control SOS1’s recruitment to the
plasma membrane and release of autoinhibition [Guerasko et al.,
2010], the distribution of identified mutations in NS supports a
picture in which the vast majority of disease-causing lesions affect the
stability of the intramolecular interactions that maintain SOS1 in an
autoinhibited state by at least two major distinct mechanisms.
A first class of mutations includes lesions predicted to promote
conformational rearrangements of domains that reduce the enzyme
self-inhibition by impairing proper masking of the distal RAS
Table 1. SOS1 Exonic Indels and Missense Changes Identified in the Study
Exon Nucleotide change Amino acid change Domain Notes Number of cases
Mutations
4 c.322G4A p.Glu108Lys HF 2, fam.unknown
5 c.508A4G p.Lys170Glu HF 1, sporadic; 2, fam.unknown
7 c.797C4A p.Thr266Lys DH 1, sporadic; 3, fam.unknown
7 c.806T4C p.Met269Thr DH 3, sporadic; 2, fam.unknown
7 c.806T4G p.Met269Arg DH 1, fam.unknown
11 c.1281_1289delGAATATTGA p.Lys427_Asp430delinsAsn PH 1, fam.unknown
11 c.1294T4C p.Trp432Arg PH 1, sporadic; 1, fam.unknown
11 c.1294_1299delTGGGAG p.Trp432_Glu433del PH CTRL, NPS 1, sporadic
11 c.1297G4A p.Glu433Lys PH 3, sporadic; 3, fam.unknown
11 c.1300G4A p.Gly434Arg PH 2, fam.unknown
11 c.1300_1301delGGinsAA p.Gly434Lys PH de novo, PPhen1, SIFT1, CON 1, sporadic
11 c.1310T4C p.Ile437Thr PH de novo, PPhen11, SIFT1, CON 1, sporadic; 1, familial
11 c.1322G4A p.Cys441Tyr PH 1, fam.unknown
11 c.1430A4G p.Gln477Arg PH PPhen, SIFT, CON 2, fam.unknown
11 c.1433C4G p.Pro478Arg PH 1, sporadic
11 c.1642A4C p.Ser548Arg PH-REM linker 4, fam.unknown
11 c.1654A4G p.Arg552Gly PH-REM linker 3, sporadic; 8, fam.unknown
11 c.1655G4A p.Arg552Lys PH-REM linker 2, sporadic; 2, fam.unknown
11 c.1655G4T p.Arg552Met PH-REM linker NPS, PPhen11, SIFT1, CON 2, sporadic
11 c.1655G4C p.Arg552Thr PH-REM linker 1, fam.unknown
11 c.1656G4C p.Arg552Ser PH-REM linker 2, sporadic; 7, fam.unknwn
11 c.1660_1673delCTTGATGTAACAATinsAA p.Leu554_Met558delinsLys PH-REM linker 1, fam.unknown
15 c.2197A4T p.Ile733Phe REM 1, fam.unknown
17 c.2536G4A p.Glu846Lys CDC25 1, sporadic, 6 fam.unknown
18 c.2681C4G p.Pro894Arg CDC25 CTRL, PPhen1, SIFT, CON 1, familiala
Possibly pathogenic variants
4 c.335C4G p.Pro112Arg HF NPS, PPhen1, SIFT 1, sporadic
7 c.755T4C p.Ile252Thr DH CTRL, PPhen11, SIFT1, CON 1, familial
11 c.1264A4G p.Met422Val PH PPhen11, SIFT; CON 1, fam.unknown
11 c.1270G4A p.Glu424Lys PH PPhen1, SIFT1, CON 1, fam.unknown
11 c.1444G4C p.Gly482Arg PH PPhen1, SIFT1, CON 1, fam.unknown
11 c.1469T4G p.Leu490Arg PH CTRL, NPS, PPhen11, SIFT1, CON 1, sporadic
11 c.1490G4A p.Arg497Gln PH CTRL, PPhen1, SIFT1, CON 1, sporadicb
11 c.1646C4A p.Thr549Lys PH-REM linker PPhen1, SIFT, CON 1, fam.unknown
Unclassified variants
3 c.109A4G p.Thr37Ala HF PPhen, SIFT, CON 1, fam.unknown
11 c.1433C4T p.Pro478Leu PH PPhen1, SIFT-, CON 1, fam.unknown
15 c.2351T4C p.Ile784Thr REM PPhen11, SIFT1, CON 1, fam.unknownc
23 c.3392G4A p.Arg1131Lys C-terminus PPhen, SIFT, CON 1, fam.unknown
23 c.3418T4A p.Leu1140Ile C-terminus PPhen, SIFT, CON 1, fam.unknown
24 c.3769A4G p.Thr1257Ala C-terminus PPhen, SIFT, CON 1, fam.unknown
Nucleotide numbering reflects cDNA numbering with 1 corresponding to the A of the ATG translation initiation codon in the reference sequence (NM_005633.3). Exon 2
corresponds to the first protein coding exon. Novel mutations are in bold.
aVariant inherited from an affected parent.
bVariant inherited from an apparently unaffected parent.
cVariant concomitant with the disease-causing p.Met269Arg change.
HF, histone folds; DH, DBL homology domain; PH, plekstrin homology domain; REM, RAS exchanger motif, CDC25, CDC25 domain. Fam.unknown, familial status
unknown; NPS, unavailable parental DNA samples. CTRL, variant not occurring inZ300 population-matched unaffected subjects; de novo, variant demonstrated to occur de
novo by DNA genotyping of unaffected parents; PPhen11, amino acid change predicted to be ‘‘probably damaging’’ by PolyPhen; PPhen1, amino acid change predicted to be
‘‘possibly damaging’’ by PolyPhen; PPhen, amino acid change predicted to be ‘‘benign’’ by Polyphen; SIFT1, amino acid change predicted to ‘‘affect protein function’’ by
SIFT; SIFT, amino acid change predicted to be ‘‘tolerated’’ by SIFT; CON, variant at a conserved residue.
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binding site or by acting on the allosteric control of catalytic activity.
Within this class, a first group of mutations (Class 1A: p.Thr266Lys,
p.Met269Arg/Thr, p.Lys728Ile, p.Trp729Leu, and p.Ile733Phe)
involve residues that participate in the autoinhibitory interaction
of the DH and REM domains blocking RAS access at the allosteric
site, or are closely located to them (Fig. 2A). These mutations are
predicted to affect the stability of the inactive conformation of the
protein directly by disrupting the inhibitory interdomain bonding
network at the distal site. Among these, the most recurrent
mutations affect Met269 (10% of total cases), which interacts
directly with residues of the REM domain implicated in RAS
binding [Sondermann et al., 2004]. Of note, Lys728 and Trp729 are
among these, and Ile733 is very close to these residues; therefore,
their substitution could also affect the REM’s affinity for GTP-
bound RAS in addition to the stability of the DH-REM interface.
Indeed, the drastic p.Trp729Glu substitution has been shown to
inhibit RAS binding to the REM domain [Sondermann et al., 2004].
This might be related to the fact that within this group, mutations
affecting residues located at the DH surface appear to be more
common (15% of total changes) compared to those affecting the
REM surface (2%). Among the probably pathogenetic variants, the
p.Ile252Thr substitution could be included in this group. Ile252 is an
invariant residue placed within a hydrophobic core of the DH
domain, which also involves Thr215, Leu219, Ile249, Tyr295, and
Tyr298. Structural perturbation of the DH fold is expected to
destabilize the masking of the distal RAS binding site.
A second mutation group includes lesions affecting the
interaction between the HF, DH, and PH domains, thus
perturbing the overall autoinhibited conformation in which the
HF and DH domains block the distal RAS binding site [Guerasko
et al., 2010] (Class 1B: p.Lys170Glu, p.Tyr337Cys, p.Ile437Thr,
p.Cys441Tyr, p.Ser548Arg, p.Leu550Pro, p.Arg 552Gly/Thr/Met/
Lys/Ser, p.Leu554_Met558delinsLys, and probably pathogenetic
variants p.Met422Val, p.Arg497Gln, and p.Thr549Lys) (Fig. 2B).
Within this group, mutations of residues 548–558 are the most
recurrent. This stretch corresponds to the helical linker connecting
the PH and REM domains, which contributes structurally to the
maintenance of the autoinhibited conformation by interacting with
the HF and DH domains [Guerasko et al., 2010]. For instance,
Arg552 interacts directly with the side chains of Asp140 and Asp169
of the HF domain, and mutation of either Arg552 or Asp140 was
demonstrated to completely abolish the interaction between these
domains [Sondermann et al., 2005]. A similar effect might be
predicted for the recurrent Lys-to-Glu change affecting codon 170
within the HF domain, and possibly for the p.Arg497Gln
substitution in the PH domain, because the electrostatic interactions
between these two residues located at the HF-PH domain interface
(but also close to the helical linker) contribute to stabilizing the HF
domain’s orientation. Similarly, substitution of residues Ile437 and
Cys441 might affect the PH domain’s structure in the region of the
domain facing toward the HF domain and possibly cause a
reorientation of the latter. Finally, residue Tyr337 is located at the
PH–DH interface, and thus probably contributes to stabilizing the
DH domain orientation. The p.Phe78Cys change (and possibly
p.Met422Val) can also be included in this group. Substitution of the
highly conserved Phe78, which is an unexposed HF residue
contributing to a hydrophobic core (involving Leu55, Leu59,
Val74, Val133, and Ile137), might structurally perturb the region
of the HF domain at its interface with the helical linker. The
p.Met422Val change, on the other hand, might perturb the structure
of the PH domain, thus perturbing the PH–HF interaction.
The third group of class 1 mutations is formed by residues of
the REM domain, interacting with the helical hairpin of the
CDC25 domain, which contributes to the allosteric structural
switch [Freedman et al., 2006], and whose conformation is
essential for both RAS binding to the active site and nucleotide
exchange [Hall et al., 2001; Margarit et al., 2003] (class 1C:
p.Phe623Ile and p.Tyr702His) (Fig. 2C). A single mutation has
been identified to affect Phe623, a highly conserved residue of the
REM domain located at the interface with the CDC25 domain.
This residue is part of an extended hydrophobic groove of the
REM domain that accommodates the side chains of two
hydrophobic residues (Ile956 and Phe958) of the helical hairpin
of the CDC25 domain. Such a hydrophobic interaction has been
demonstrated to be important for the correct orientation of the
helical hairpin, and for SOS1’s catalytic activity [Hall et al., 2001].
Based on these observations, it can be hypothesized that the
p.Phe623Ile substitution might perturb the catalytic activity of the
CDC25 domain by acting either on RAS binding at the catalytic
site, on the domain’s catalytic efficiency or on allosteric control. A
similar effect might be associated with substitution of the
invariant Tyr702, which is located within the REM domain at
the interface with the CDC25 domain, in close proximity to the
region of the latter that undergoes the conformational switch
promoted by RAS binding at the distal site.
Although the primary anchorage of SOS1 to the plasma
membrane is mediated by docking of its C-terminal region to SH3
domain-containing adaptor proteins (e.g., GRB2) that bind to the
activated receptors, additional anchorage sites at the membrane
are provided by the phosphatidylinositol-4,5-phosphate (PIP2)-
and phosphatidic acid (PA)-binding sites within the PH domain
[Chen et al., 1997; Zhao et al., 2007; Zheng et al., 1997], and by an
extended positively charged surface of the HF domain that
interacts with anionic membranes, and possibly also binds PA and
PIP2 [Guerasko et al., 2010; Yadav and Bar-Sagi, 2010]. These sites
appear to have complementary roles: whereas those within the PH
domain mediate SOS1’s targeting to the membrane, the latter are
thought to activate the GEF at the membrane. In the autoinhibited
structure of SOS1, the positively charged site of the HF domain is
not oriented in a way that would allow membrane binding
[Guerasko et al., 2010]. This finding suggests the possibility that
the reorientation of the PA-binding site of the HF domain might
be coupled to the destabilization of the autoinhibited conforma-
tion of the protein, permitting SOS1’s activation through RAS
binding at the allosteric site [Guerasko et al., 2010; Yadav and
Bar-Sagi, 2010]. Class 2 mutations include changes that are
predicted to enhance SOS1’s catalytic function by membrane-
dependent mechanisms. Within this class, a first group is
predicted to perturb the self-inhibiting orientation of the HF
domain by affecting solvent exposed residues located within the
positively charged surface of the HF domain, thus favoring its
membrane binding (class 2A: p.Pro102Arg and p.Glu108Lys, and
probably pathogenetic variant p.Pro112Arg) (Fig. 2D). Signifi-
cantly, these mutations introduce a positively charged amino acid
(arginine or lysine) enhancing the positive electrostatic potential
of the HF surface. In particular, Glu108 is adjacent to the PA-
binding motif and its substitution by lysine generates a contiguous
patch of positively charged residues that was recently demon-
strated to potentiate membrane binding [Yadav and Bar-Sagi,
2010]. A similar perturbing effect would be predicted for the
c.305C4G and c.335C4G missense changes affecting the closely
located Pro102 and Pro112 residues.
A second group includes mutations affecting the membrane-
binding surface of the PH domain (class 2B: p.Lys427_Asp430delin-
sAsn, p.Trp432Arg, p.Trp432_Glu433del, p.Glu433Lys, p.Gly434Arg/
Lys, p.Gln477Arg/His, p.Pro478Arg, p.Pro481_Gly482insArgLeuPro,
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Figure 2. Detailed analysis of structural perturbations resulting from Noonan syndrome-causing amino acid substitutions. A: Class 1 mutations
affecting residues at the distal RAS binding site. The cartoon includes the DH (sandy brown) and REM (dark green) domains only. Affected residues are
shown in red. The autoinhibitory binding network includes the hydrophobic interaction between residues Met269 (DH) and Trp729 (REM), both mutated in
NS, and between the former and Leu687 (green). Leu690, Val697, Ile718, and Ile736 are hydrophobic residues (cyan) that interact with Ile733 (REM).
Mutated residues Thr266 (DH) and Lys728 (REM) face each other. Substitution of Thr266 by lysine would create an electrostatic repulsion with Lys728. The
unclassified variant Leu252 contributes to a hydrophobic core with residues Tyr215, Leu219, Ile249, Tyr295, and Tyr298 (purple), whose disruption is
expected to perturb considerably the DH domain surface interacting with the REM domain. B: Class 1B mutations. The cartoon includes the HF (sky blue),
DH (sandy brown), and PH (magenta) domains and the PH-REM helical linker (gray). Relevant affected residues are shown in red. Met422 and Ile437 (PH)
participate in a hydrophobic bonding network with residues Ile425, Phe464, and Leu467 (cyan, see also the inset). Hydrophobic interaction between Tyr337
and Met538 (green) contributes to the binding network stabilizing the interaction between the PH and DH domains. Other interdomain interactions involve
Leu550 and residues of the DH and PH domains, Val225, Leu221, Phe226, and Tyr546 (gray), Arg552, and residues of the HF domain, Asp140 and Asp169
(orange), Ser548 and Asp169, and Lys170, and residues of the PH domain, Arg497 and Lys498 (blue). Phe78 participates to the hydrophobic interaction
involving residues of the HF domain core located close to the PH domain and PH-REM linker (Leu55, Leu59, Val74, Val133, and Ile137; purple). C: Class 1
mutations affecting the REM domain region (dark green) interacting with the CDC25 domain (blue). The helical hairpin (residues 929–978) implicated in the
conformational switch (green) and residues interacting with RAS at the active site (light blue) are shown. Phe623 hydrophobically interact with Ile 601,
Leu613, Phe627, Ile956, and Phe958 (cyan). The hydrogen bond between Tyr702 and Ser802 (orange) is also shown. D: Class 2 mutations affecting the HF
domain. The left panel shows the HF (light blue), DH (sandy brown), and PH (plum) domains. The HF surface colored according to the electrostatic
potential (from red at 3kT/e to blue at 13kT/e) is also shown (right panel). Mutations affect solvent exposed residues (yellow side chains, left panel;
yellow circles, right panel) located in a region that has a positive electrostatic potential (right panel), and has been implicated in membrane binding. E:
Class 2 mutations affecting the PH domain. The left panel includes the PH domain (plum) only. The PH surface, colored according to the electrostatic
potential (from red at 5kT/e to blue at 15kT/e) is also shown (left panel). Affected residues are shown in yellow (side chains, left panel; circles, right
panel). Residues that are predicted to bind to PIP2 [Zheng et al., 1997], Lys456, Arg459, Lys472, and Arg489, are shown in green (circled in the right panel),
whereas the PA-interacting region (residues 472–483) [Zhao et al., 2007] is shown in orange (circled in the right panel). F: Class 3 mutations. The cartoon
includes the REM (dark green) and CDC25 (blue) domains only (residues 567–1049). Affected residues are shown in green. Residues implicated in RAS
binding at the catalytic site are shown (light blue). Glu846 and Pro894 are placed distally from the active site and regions implicated in the conformational
rearrangement of the CDC25 domain. Glu846 electrostatically interacts with Arg1026 and Lys 1029 (orange).
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and probably pathogenetic variants p.Glu424Lys, p.Gly482Arg, and
p.Leu490Arg) (Fig. 2E). As anticipated, two sites within the PH
domain have been identified [Chen et al. 1997; Zhao et al., 2007;
Zheng et al., 1997]. Both sites contribute to membrane recruitment
of SOS1 and are required for efficient GEF activity. We noticed that
the vast majority of mutations affecting the PH domain involved
solvent-exposed residues within two adjacent regions (i.e., residues
424–436 and 473–493) that do not overlap spatially with the PIP2-
binding site, which is constituted by residues Lys456, Arg459, Lys472,
and Arg489 [Zheng et al., 1997]. A first cluster of mutations affected
residues Gln477, Pro478, Pro481, and Gly482, which are placed
within the PA-binding site encompassing residues 472–483 [Zhao
et al., 2007], whereas the second cluster affect residues Glu424,
Lys427–Asp430, Trp432–Gly434, and Leu490. Of note, the nature of
the substitution seemed to be critical because all missense mutations
affecting these regions resulted in the introduction of a positively
charged residue. In two cases (Gly434, Gln477), multiple lesions were
predicted to introduce either an arginine or a lysine, further
indicating a specific role for the introduced charged residue. In
additional two cases, including the recurrent c.1297G4A
(p.Glu433Lys), the positively charged residue replaced a negatively
charged amino acid. Similarly, the three identified in-frame indels
were predicted to increase the electrostatic potential of the postulated
membrane interaction surface. Based on established evidence
supporting an absolute requirement of SOS1’s recruitment to the
plasma membrane for RAS activation in response to an extracellular
stimulus [Zhao et al., 2007], this nonrandom distribution and type of
lesions strongly suggest that their pathogenetic effect is related to a
strengthened binding of SOS1 to PA, PIP2 and/or other membrane
phospholipids, and consequently, to a more stable recruitment of the
protein at the membrane, which in turn would enhance the duration
and/or amplitude of GEF function.
Only two disease-causing mutations have been found to affect
the CDC25 domain so far. The affected residues (i.e., Glu846 and
Pro894) are placed in close proximity to each other, and distally
from the two RAS binding sites and regions implicated in the
conformational rearrangement of the domain promoting RAS’s
binding to the active site (Fig. 2F). The high recurrence of the
p.Glu846Lys change indirectly documents a relevant role of this
region in SOS1’s function. This amino acid substitution has
recently been documented to profoundly perturb intracellular
signaling [Chen et al., 2010]. Available crystal data, however, do
not allow us to infer any functional effect for these mutations, as
well as for unclassified variants affecting residues in this domain
(Ile784, Gln977, and Ser1000) or at the C-terminus (Arg1131,
Leu1140, and Thr1257). We noted that Arg1131 is adjacent to
Ser1132, which is one of the identified growth factor-induced,
MAPK-mediated phosphorylation sites of SOS1 [Corbalan-Garcia
et al., 1996]. These sites cluster within a small region that contains
the proline-rich SH3-binding sites implicated in GRB2 binding.
Of note, phosphorylation of these sites has been demonstrated to
reduce SOS1’s binding affinity for GRB2, and it could be
speculated that mutations altering the recognition motif at these
sites might affect phosphorylation and promote enhanced GRB2
binding. Similarly, Leu1140 and Thr1257 cluster within this
region. Based on evidence suggesting that this region possibly
exerts an autoinhibitory effect on SOS1’s activity [Aronheim et al.,
1994; Wang et al., 1995], it can be speculated that lesions affecting
this region might perturb such an inhibitory mechanism.
Finally, available structural data did not allow us to identify any
functional clue for the p.Asp309Tyr NS-causing substitution as
well as for the unclassified sequence variants affecting Thr37 and
Thr378 residues.
Phenotypic Spectrum and Genotype–Phenotype
Correlations of SOS1 Mutations
Extensive clinical information was obtained for 39 subjects with
NS and bona fide SOS1 mutations, including individuals recruited in
this study (group 1, cases NS01 to NS25) and reexamined subjects of
our original study (NS26 to NS39) [Tartaglia et al., 2007] (Supp.
Table S3). Overall, analysis of the clinical data confirmed previous
observations from our group and others indicating that mutations in
SOS1 are associated with a distinctive phenotype that unambiguously
falls within the NS clinical spectrum, but is characterized by a high
prevalence of ectodermal features (keratosis pilaris/hyperkeratotic
skin, sparse eyebrows, and sparse, generally thin and curly scalp hair)
(84% of cases), and a relatively low occurrence of cognitive deficits
(11% of cases) compared to what is observed in the NS general
population. Of note, in two cases mental retardation was potentially
attributable to critical illness during infancy. In two additional
subjects, the intelligence quotient was borderline to the lower limit of
the normal range with impairment of linguistic skills and
oculomanual coordination in one subject, and delay of speech in
the other (Supp. Table S3). We also confirmed our previous
observation indicating a relatively low prevalence of subjects
exhibiting reduced growth (length/stature below the third centile)
(29% of cases). In these subjects, reduced growth was invariably
associated with delayed bone age. Remarkably, more than one-third
of subjects with mutated SOS1 allele exhibited fetal macrosomia,
which however, did not appear to correlate with the extent of their
postnatal growth, being length/stature in these subjects below the
third centile in a comparable proportion of cases, compared with
subjects without this feature (3/14 vs. 7/24, Fisher’s exact prob-
ability5 0.45). Of note, SOS1 mutation-positive subjects displayed a
more pronounced growth failure (45% of cases) as newborns, which
was not generally secondary to poor sucking and/or swallowing.
SOS1mutation-positive subjects displayed typical facial features
(Fig. 3). Macrocephaly was, however, overrepresented compared
to the general NS population (61 vs. 12%) [Sharland et al., 1992].
Among these subjects, cardiac defects were frequently observed
(89% of cases), with PS, ASD. and VSD being the most recurrent
anomalies, while prevalence of HCM was comparable to that
observed in PTPN11 mutation-associated NS, occurring in less
than 10% of cases [Sarkozy et al., 2009b]. Of note, PS was found
to be frequently associated with ASD (35% of cases). Finally, two
subjects were documented to present with mandibular multiple
giant cell lesions (MGCLs), which were associated with multiple
tumors, including abdominal rhabdomyosarcoma, cerebral glio-
ma, and skin granular cell tumors in one subject.
The analysis of distribution of the major clinical features among
SOS1 mutation-positive subjects documented a significantly
higher prevalence of fetal macrosomia in subjects with class 1B
mutations compared to individuals with class 1A mutations
(Fisher’s exact probability5 0.024). We failed in identifying any
other significant genotype–phenotype correlation. Based on the
relatively small size of the cohort analyzed, however, the
occurrence of other associations between specific features and
individual SOS1 lesions or mutation clusters cannot be ruled out.
Discussion
In this report, we have expanded the available information about
the molecular diversity of SOS1 mutations underlying NS, and
have provided a more comprehensive assessment of the clinical
features associated with those molecular lesions. We also explored
systematically the predicted structural consequences of NS-causing
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SOS1 defects, developing a classification of these gene lesions based
on the predicted role of affected residues and functional
consequences derived from the nature of the amino acid change.
Combined with data from previous surveys, our findings
indicate that SOS1 mutations are almost always missense changes,
although we documented that small in-frame indels occur in a
small proportion of cases. Available mutation records (data
updated to July 2010) revealed a complete absence of nonsense,
frameshift, and splicing defects, which is consistent with
functional characterization of a panel of NS-causing SOS1
mutations [Chen et al., 2010; Guerasko et al., 2010; Roberts
et al., 2007; Tartaglia et al., 2007], and further support their
activating role on SOS1 functional dysregulation in disease
pathogenesis. Moreover, the accumulated data strongly indicated
that specificity in the amino acid substitution is relevant to the
functional dysregulation of the protein. Specifically, occurrence of
invariant amino acid changes was observed for several residues
and accounted for approximately 50% of total events, strongly
suggesting a specific role for the introduced residue. Exemplifying
this is the observation of positively charged amino acids that were
observed invariantly to replace solvent exposed residues located
within the HF and PH domains (i.e., Glu108, Trp432, Glu433, and
Gly434), which provides strong evidence for the electrostatic
nature of the perturbing effect of those mutations on SOS1
functional dysregulation. On the other hand, the identity of
substitution did not seem to be critical in other cases (e.g., most
mutations affecting the helical linker connecting the DH and PH
domain), indicating a crucial role for the amino acid residue being
replaced. This is the case of Arg552, for which all but one amino
acid substitutions resulting from a single base change affecting this
codon have been documented to cause NS.
Based on SOS1’s crystal structure and mechanism of activation
[Guerasko et al., 2008, 2010], the nonrandom distribution pattern
of altered residues and nature of substitutions indicate that NS-
causing mutations dysregulate SOS1’s GEF function by at least two
major mechanisms. As originally reported by Roberts et al. [2007]
and Tartaglia et al. [2007], a large fraction of mutations was found
to cluster in regions of the protein that participate in the
interdomain binding network that maintain SOS1 in its catalytically
inactive conformation (class 1 mutations). Among these, mutations
can affect either residues directly implicated in the autoinhibitory
interaction between the DH and REM domains that impair GTP-
RAS binding at the distal site (or residues closely located to them),
or residues located within the DH–PH helical linker or regions of
the HF, DH, and PH domains that contribute to stabilizing the HF,
DH, and REM interdomain binding network that maintains SOS1
in its catalytically inactive conformation. Of note, this study
recognized a third group of class 1 mutations that were found to
specifically affect residues of the REM domain located at the
interface with regions of the CDC25 domain identified to undergo
the GTP-RAS binding-induced conformational rearrangement
required for both RAS binding to the active site and nucleotide
Figure 3. Facial dysmorphism and other features of subjects with Noonan syndrome heterozygous for mutations in the SOS1 gene. SOS1
mutation-positive subjects generally exhibit typical facial features, including macrocephaly, hypertelorism, ptosis, downslanting palpebral
fissures, sparse eyebrows with keratosis pylaris, a short and broad nose with upturned tip, low-set and posteriorly angulated ears, and high
forehead commonly associated with bitemporal narrowing and prominent supraorbital ridges. Curly hair is present in most of the patients. Other
common features include pectus anomalies (NS10, NS19, NS37), short and/or webbed neck (NS6, NS10, NS19, NS22, NS38), and cubitus valgus
(NS37). Keloid scars (NS16), recurrent hemorrhages (NS18), and deep plantar creases (NS38) also occur in these subjects. In some infants, the
face is suggestive of cardiofaciocutaneous syndrome due to the coarseness of features (NS39).
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exchange reaction. Although the effect of these amino acid
substitutions on RAS binding at the catalytic site or on the
domain’s catalytic efficiency cannot be ruled out, we hypothesize
that these mutations might upregulate SOS1’s catalytic activity by
weakening the inhibitory allosteric control on the active site.
Strikingly, our analysis also allowed us to discern a previously
unrecognized class of mutations affecting solvent exposed residues
located within the membrane oriented surface of the PH domain
and a positively charged surface of the HF domain, and predicted to
enhance SOS1’s catalytic function by distinct membrane-dependent
mechanisms. Although the complex process of SOS1’s catalytic
activation has not been characterized in detail, available structural
and functional data indicate that the two major events controlling
SOS1’s function, that is, protein recruitment to the plasma
membrane and release of autoinhibition, are linked. Membrane
translocation of SOS1 is promoted by binding of the protein to
activated cell surface receptors via SH3 domain recognition sites at
the C-terminus of SOS1 that mediate its interaction with adaptor
proteins. Additional anchorage sites at the membrane, however, are
also provided by the PH and HF domains. Experimental and
structural data indicate that two distinct sites within the PH
domains bind to PIP2 and PA, and contribute significantly to
SOS1’s targeting to the membrane [Chen et al., 1997; Zhao et al.,
2007]. On the other hand, in the SOS1’s autoinhibited structure, the
positively charged surface of the HF domain is not oriented in a way
that would allow membrane binding, suggesting the possibility that
reorientation of the HF domain in the membrane-bound
conformation might destabilize HF’s interaction with the REM
domain, unmasking the distal RAS binding site [Guerasko et al.,
2010; Yadav and Bar-Sagi, 2010]. Based on this model, the
molecular spectrum of disease-causing mutations affecting the
PH and HF domains are predicted to favor the membrane-
dependent electrostatic switch leading to a productive reorientation
of the protein in the plane of the membrane and consequent release
of autoinhibition at the regulatory RAS binding site. In this
scenario, class 2 mutations would enhance the simultaneous
engagement of the membrane by the PIP2- and PA-binding pockets
of the PH domain and the positively charged surface of the HF
domain, synergizing to increase the stability of SOS1 translocation
at the membrane and catalytic activation. Specifically, the
pathogenetic effect of this class of mutations affecting the PH
domain would be related to a more stable recruitment of the
protein at the membrane, while the introduction of an arginine or
lysine residue within the positively charged surface of the HF
domain would favor a spatial reorientation of the domain
weakening its inhibitory function. Consistent with this model,
Guerasko and coworkers [2010] demonstrated that the Glu108Lys
substitution promotes enhanced SOS1’s GEF activity in a PIP2-
dependent manner, and elegantly provided evidence for a role of
nonspecific electrostatic interactions of the HF domain with the
membrane in release of autoinhibition and activation of SOS1.
The present mutation scanning of a clinically well-characterized
cohort of subjects with features fitting or highly suggestive of NS,
and negative for mutations in PTPN11, RAF1, and KRAS,
confirmed our previous estimate of SOS1 mutation prevalence,
indicating that defects in this gene account for approximately 10%
of NS. Moreover, detailed clinical examination of 39 mutation-
positive individuals, including data from clinical reexamination of
14 subjects constituting our original cohort [Tartaglia et al., 2007],
provided a more complete assessment of the phenotypic variation
associated with these molecular lesions, and strengthened the
specific association with ectodermal involvement (84%), and
decreased prevalence of cognitive deficits (11%) documented in
previous reports [Denayer et al., 2010; Roberts et al., 2007;
Tartaglia et al., 2007; Zenker et al., 2007a]. A major finding also
regarded the relatively lower prevalence of short stature/length
below the third centile in these subjects (29%) compared to the
overall NS population, for which an estimate of 70% is generally
reported. This percentage is lower than in other studies, in which
the prevalence ranged from 31 to 64% [Denayer et al., 2010;
Roberts et al., 2007; Zenker et al., 2007a]. Based on the different
recruitment strategies utilized, this discrepancy might be due, in
part, to differences in patient selection (e.g., recruitment
performed by pediatric endocrinology units vs. cardiology units).
It should be noted, however, that this disagreement might be also
related to a sampling bias depending on the age distribution
among cohorts. In NS, although birth length is typically normal,
growth parameters usually drop below the third centile during the
first years of life. Because there is often some attenuation and/or
delay of the pubertal growth spurt, the prevalence of short stature
in NS is expected to be highest during the age of normal puberty.
Because of the delay in bone age, however, many patients have
some catchup growth in their late teens. As we documented a
delay in bone age in all subjects with length/stature below the third
centile, a significant variation in the estimate of the growth status
between cohorts differing considerably in age distribution would
be expected, because the estimate of reduced growth prevalence in
any NS cohort would be sensitive to the composition of the cohort
in terms of proportion of pediatric versus adult subjects.
We observed the occurrence of multiple tumors (i.e., MGCLs,
abdominal rhabdomyosarcoma, cerebral glioma, and granular cell
tumors of the skin) in one of the SOS1 mutation-positive subjects
included in the study. It has been established that NS patients are at
increased risk of developing childhood myeloproliferative disease
(i.e., juvenile myelomonocytic leukemia) and acute leukemia
[Tartaglia and Gelb, 2005], and that this specific association is
strictly linked to a specific class of activating germline mutations in
the PTPN11 gene [Tartaglia et al., 2006]. Occurrence of
neuroblastoma, glial tumors, and rhabdomyosarcoma in subjects
with NS, however, has also been reported [Kratz, 2009].
Remarkably, although mutations in SOS1 have previously been
considered to be more benign in terms of risk of malignancy than
those in other genes in the RAS/MAPK pathway (e.g., PTPN11,
HRAS, KRAS, and NF1) [Swanson et al., 2008], a significant high
occurrence of solid tumors, particularly embryonal rhabdomyo-
sarcoma, has recently been reported in subjects with NS due to a
mutated SOS1 allele [Denayer et al., 2010; Hastings et al., 2010;
Jongmans et al., 2010]. The present finding is in line with these
recent reports, and provides further evidence that subjects
heterozygous for SOS1 mutations may have a significant risk for
certain solid tumors. Of note, MGCLs were observed in one
additional SOS1 mutation-positive subject of the present cohort.
MGCLs are benign tumor-like lesions most frequently affecting the
jaws but also occurring in other bones or soft tissues. They consist
of an osteoblast-like cell population representing the proliferating
tumor cells producing cytokines inducing the maturation of a
subset of phagocytes into osteoclast-like giant cells [de Lange et al.,
2007]. Although the incidence of MGCLs in patients with NS is not
known, they were originally linked to a narrow spectrum of
germline PTPN11 mutations [Jafarov et al., 2005; Lee et al., 2005;
Tartaglia et al., 2002]. In recent years, however, their co-occurrence
in NS (and other RAS-opathies) has been extended to other genes
encoding transducers with roles in the RAS–MAPK pathway, with
SOS1 being the most frequently mutated gene [Beneteau et al.,
2009; Hanna et al., 2009; Neumann et al., 2009], indicating that
SOS1 is a major predisposing gene for MGCLs in NS.
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One patient in the present cohort, who was heterozygous for the
de novo c.1297G4A missense change (p.Gly434Lys), presented with
gingival hypertrophy. Interestingly, a SOS1 frameshift mutation
(c.3248–3249insC) predicting a truncated protein lacking the
C-terminal region encompassing the SH3 domain-binding and
MAPK phosphorylation sites, was previously documented to be
responsible for a form of hereditary gingival fibromatosis (HGF1;
MIM] 135300), a genetically heterogeneous benign gingival
overgrowth condition, in a large family [Hart et al., 2002].
Consistent with the negative modulatory role of the C-terminal
region on SOS1 function [Corbalan-Garcia et al., 1998; Wang
et al., 1995], the SOS1 mutant was demonstrated to localize at the
plasma membrane constitutively and sustain the activation of
RAS–MAPK signaling, linking the gingival overgrowth to
enhanced SOS1-mediated signal flow through RAS [Jang et al.,
2007]. Although further studies are required to appreciate more
precisely the peculiar effect of the HGF1-associated mutation on
SOS1 functional dysregulation and its specific effect on gingival
growth, the present finding provides further evidence in support
of a relation between RAS/MAPK signaling dysregulation and
gingival hypertrophy.
Excluding Down syndrome, NS is the most frequent develop-
mental disorder associated with congenital cardiac disease. Among
SOS1mutation-positive individuals, cardiac defects occurred in the
majority of cases (485%), which is consistent with previous
studies [Denayer et al., 2010; Roberts et al., 2007; Tartaglia et al.,
2007; Zenker et al., 2007a]. Similar to what observed in NS subjects
with PTPN11mutations [Tartaglia et al., 2002; Zenker et al., 2004],
SOS1 mutation-positive patients exhibit a high prevalence of PS
(68% of cases), which was typically associated with ASD (35% of
cases), a relatively high occurrence of atrial and ventricular septal
defects (39% of cases), and a low prevalence of HCM (o10% of
cases). Based on these findings and preliminary observations
suggesting that a distinct class of mutations in NS disease might be
implicated in isolated CHDs [Greenway et al., 2009; Pandit et al.,
2007], and given the relatively ‘‘mild’’ developmental and growth
related phenotype documented in a significant proportion of SOS1
mutation-positive subjects, we evaluated the possible contribution
of germline SOS1 gene lesions in apparently nonsyndromic PS,
ASD, and VSD. Mutation analysis revealed no bona fide mutation
within these cohorts, which does not support the idea of a major
contribution of SOS1 gene defects in the pathogenesis of these
CHDs, in line with other studies documenting only a minor
contribution of germline PTPN11mutations in isolated CHDs and
HCM [Limongelli et al., 2006; Roberts et al., 2005; Sarkozy et al.,
2003, 2005; Weismann et al., 2005].
Subjects heterozygous for a mutated SOS1 allele present with
ectodermal manifestations and distinctive facial dysmorphism that
might be suggestive of CFCS in some individuals (Fig. 3) [Narumi
et al., 2008; Nystrom et al., 2008]. In these subjects, however,
cognitive deficits are generally absent or minor [Denayer et al.,
2010; Narumi et al., 2008; Tartaglia et al., 2007; Zenker et al.,
2007a; present study]. Consistent with these observations, our
mutational screening on a clinically well-characterized CFCS
cohort failed in identifying any SOS1 mutation, confirming a
previous survey indicating that SOS1 does not represent a major
gene for this disorder [Zenker et al. 2007a]. Atlhough the clinical
features of SOS1mutation-positive subjects appear to be less severe
compared to what is generally observed in CFCS, the identification
of subjects with an ‘‘overlapping’’ phenotype suggests that a clinical
continuum might be associated with defects in SOS1, as previously
documented for other disease genes implicated in RAS-opathies
[Sarkozy et al., 2009a; Zenker et al., 2007b]. On the other hand,
based on the increasing evidence documenting co-occurrence of
mutations in functionally related genes that contribute to the
severity of the phenotype [Longoni et al., 2010; Nystrom et al.,
2009; Tang et al., 2009; Thiel et al., 2009], the possibility that
mutations concomitant to those affecting SOS1 might modulate
the phenotype in these subjects cannot be ruled out. Overall, these
findings further emphasize the difficulty in identifying efficient
clinical criteria to define these disorders nosologically, and make
evident the clinical relevance of a molecular-based definition of
these clinically overlapping disorders.
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